Effects of metformin on endometrial cancer: Systematic review and meta-analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Endometrial cancer is one of the most common gynecological cancers, which is frequently preceded by atypical endometrial hyperplasia, a premalignant lesion. Metformin, an antidiabetic drug, has emerged as a new adjunctive strategy for different cancer types, including endometrial cancer. This systematic review and meta-analysis aimed to evaluate the effects of metformin in atypical endometrial hyperplasia and endometrial cancer patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Gynecol. Oncol.

Title: Gynecologic oncology

Publisher: Elsevier BV

ISSN (Electronic): 1095-6859

ISSN (Print): 0090-8258

Publication date (Electronic): October 2017

Volume: 147

Issue: 1

Affiliations

[1 ] Molecular Pharmacology Laboratory, Health Sciences Faculty, University of Brasilia, Brasilia, Brazil.

[2 ] Molecular Pharmacology Laboratory, Health Sciences Faculty, University of Brasilia, Brasilia, Brazil; Gonadal and Adrenal Diseases Clinics, University Hospital of Brasilia, University of Brasilia, Brasilia, Brazil.

[3 ] Laboratory of Oral Histopathology, Health Sciences Faculty, University of Brasilia, Brasilia, Brazil.

[4 ] Molecular Pharmacology Laboratory, Health Sciences Faculty, University of Brasilia, Brasilia, Brazil; Gonadal and Adrenal Diseases Clinics, University Hospital of Brasilia, University of Brasilia, Brasilia, Brazil. Electronic address: adlofrano@uol.com.br.

Article

Publisher Item ID: S0090-8258(17)31136-8

DOI: 10.1016/j.ygyno.2017.07.120

PubMed ID: 28760367

SO-VID: 7c8c9f55-c7ec-4e82-88ab-7ad3b5ac933b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 51

See all cited by

- Version 1